MapLight (MPLT) officer uses share withholding to cover RSU tax bill

Rhea-AI Filing Summary

MapLight Therapeutics officer Jonathan Gillis, who serves as CAAO and PAO, reported a tax-related share withholding on January 27, 2026. The transaction involved 22,050 shares of Voting Common Stock (code F) at $17.98 per share, used to satisfy tax withholding on restricted stock unit settlements.

Following this withholding, Gillis beneficially owned 248,503 shares directly. The remaining securities he holds are still subject to a lock-up agreement related to MapLight’s initial public offering, restricting most transfers for 180 days after the final prospectus dated October 26, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILLIS JONATHAN

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CAAO and PAO

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	01/27/2026		F		22,050(1)	D	$17.98	248,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MPLT officer Jonathan Gillis report?

Jonathan Gillis reported a tax-related withholding of 22,050 shares of MapLight Therapeutics Voting Common Stock. These shares were withheld by the company to cover tax obligations from restricted stock unit settlements, rather than representing an open-market sale by the officer.

How many MPLT shares does Jonathan Gillis hold after this Form 4?

After the reported transaction, Jonathan Gillis beneficially owned 248,503 shares of MapLight Therapeutics Voting Common Stock directly. This figure reflects his holdings after 22,050 shares were withheld to satisfy tax obligations on restricted stock unit awards.

What does transaction code F mean in the MPLT Form 4 filing?

Transaction code F indicates shares were withheld to pay taxes on an equity award, not sold on the market. In this case, 22,050 shares of MapLight Voting Common Stock were retained by the issuer to satisfy Gillis’s tax withholding obligations.

Is the MPLT insider transaction part of the IPO lock-up restrictions?

The filing states retained securities remain subject to a lock-up agreement tied to MapLight’s initial public offering. Under this agreement, Gillis agreed not to directly or indirectly sell or transfer most securities for 180 days after the final prospectus dated October 26, 2025.

Who is the insider involved in this MPLT Form 4 and what is his role?

The reporting person is Jonathan Gillis, an officer of MapLight Therapeutics, Inc. listed with the title CAAO and PAO. He filed the Form 4 as a single reporting person for a tax-withholding transaction involving company Voting Common Stock.

Did the MPLT Form 4 report any derivative securities transactions?

The provided Form 4 details a non-derivative transaction in Voting Common Stock only. While the form includes a table structure for derivative securities, no specific derivative security acquisitions or dispositions are reported in the excerpted transaction data.